Kymera Therapeutics, Inc. (KYMR)
108.69
+3.91
(+3.73%)
USD |
NASDAQ |
Oct 19, 13:01
Kymera Therapeutics Net Income (Quarterly) : -61.21M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -61.21M |
| March 31, 2026 | -69.23M |
| December 31, 2025 | -86.98M |
| September 30, 2025 | -82.18M |
| June 30, 2025 | -76.61M |
| March 31, 2025 | -65.58M |
| December 31, 2024 | -70.75M |
| September 30, 2024 | -62.49M |
| June 30, 2024 | -42.06M |
| March 31, 2024 | -48.56M |
| December 31, 2023 | -14.37M |
| September 30, 2023 | -52.87M |
| June 30, 2023 | -38.80M |
| March 31, 2023 | -40.93M |
| Date | Value |
|---|---|
| December 31, 2022 | -34.86M |
| September 30, 2022 | -43.00M |
| June 30, 2022 | -40.26M |
| March 31, 2022 | -36.68M |
| December 31, 2021 | -33.90M |
| September 30, 2021 | -28.58M |
| June 30, 2021 | -24.66M |
| March 31, 2021 | -13.08M |
| December 31, 2020 | -12.68M |
| September 30, 2020 | -7.986M |
| June 30, 2020 | -13.99M |
| March 31, 2020 | -10.93M |
| December 31, 2019 | -11.51M |
| September 30, 2019 | -11.42M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | -106.63M |
| Twist Bioscience Corp. | -35.05M |
| Beam Therapeutics, Inc. | -122.68M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 65.00M |
| Total Expenses (Quarterly) | 126.21M |
| EPS Diluted (Quarterly) | -0.6235 |
| Enterprise Value | 8.062B |
| Gross Profit Margin (Quarterly) | 96.88% |
| Profit Margin (Quarterly) | -94.17% |
| Earnings Yield | -2.98% |
| Normalized Earnings Yield | -2.954 |